These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34180463)

  • 1. Clinical effectiveness of house dust mite immunotherapy in mono- versus poly-sensitised patients with allergic rhinitis: a systematic review and meta-analysis.
    Kim JY; Hwang D; Jang M; Rhee CS; Han DH
    Rhinology; 2021 Aug; 59(4):352-359. PubMed ID: 34180463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of immunotherapy on cross-reactivity between house dust mite and other allergens in house dust mite -sensitized patients with allergic rhinitis.
    Zhao L; Zhang Y; Zhang S; Zhang L; Lan F
    Expert Rev Clin Immunol; 2021 Sep; 17(9):969-975. PubMed ID: 34388949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
    Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
    Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The changes in different symptom scores during subcutaneous immunotherapy in Chinese house dust mite allergic patients: a two-year, observational study.
    Tu Y; Zhang H; Zhao L; Jin P; Zi X; Li T; Shi L; Zhi L
    J Laryngol Otol; 2019 Mar; 133(3):213-219. PubMed ID: 30674357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific IgE and IgG4 Profiles of House Dust Mite Components in Allergen-Specific Immunotherapy.
    Yang L; Yang Y; Xu Q; Zhang W; Jiang Q; Li W; Wang Y; Ma D; Lin X; Sun B; Zhu R
    Front Immunol; 2021; 12():786738. PubMed ID: 35197963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. House dust mite allergen immunotherapy for monosensitized versus polysensitized patients with allergic rhinitis: A systematic review and meta-analysis.
    Phinyo P; Krikeerati T; Wongyikul P; Lao-Araya M; Thongngarm T
    Asian Pac J Allergy Immunol; 2022 Dec; 40(4):337-352. PubMed ID: 36278778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
    Calderon MA; Casale TB; Nelson HS; Demoly P
    J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
    Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
    J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
    Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
    J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.
    Demoly P; Emminger W; Rehm D; Backer V; Tommerup L; Kleine-Tebbe J
    J Allergy Clin Immunol; 2016 Feb; 137(2):444-451.e8. PubMed ID: 26292778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SQ house dust mite sublingual immunotherapy for the treatment of adults with house dust mite-induced allergic rhinitis.
    Meteran H; Backer V
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1127-1133. PubMed ID: 31584839
    [No Abstract]   [Full Text] [Related]  

  • 12. Sublingual immunotherapy in patients with house dust mite allergic rhinitis: prospective study of clinical outcomes over a two-year period.
    Soh JY; Thalayasingam M; Ong S; Loo EX; Shek LP; Chao SS
    J Laryngol Otol; 2016 Mar; 130(3):272-7. PubMed ID: 26781592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. House dust mite sublingual immunotherapy in allergic rhinitis.
    Cho SW; Han DH; Kim JW; Kim DY; Rhee CS
    Immunotherapy; 2018 Jun; 10(7):567-578. PubMed ID: 29562802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases.
    Ferrando M; Bagnasco D; Passa-Lacqua G; Puggioni F; Varricchi G; Canonica GW
    Curr Pharm Biotechnol; 2017; 18(5):378-383. PubMed ID: 28413977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of 300 IR house dust mite immunotherapy as a function of disease activity: Tertile analysis in clinical trials.
    Devillier P; Demoly P; Gentil C; Bergmann KC; Casale TB; Okamoto Y; Pfaar O
    Clin Exp Allergy; 2024 May; 54(5):329-338. PubMed ID: 38545699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world evidence of subcutaneous allergoid immunotherapy in house dust mite-induced allergic rhinitis and asthma.
    Jutel M; Brüggenjürgen B; Richter H; Vogelberg C
    Allergy; 2020 Aug; 75(8):2050-2058. PubMed ID: 32080856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Functional IgE-Blocking Factor Induced by Allergen-Specific Immunotherapy Correlates with IgG4 Antibodies and a Decrease of Symptoms in House Dust Mite-Allergic Children.
    Zhao D; Lai X; Tian M; Jiang Y; Zheng Y; Gjesing B; Zhong N; Spangfort MD
    Int Arch Allergy Immunol; 2016; 169(2):113-20. PubMed ID: 27049773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. House dust mite SCIT reduces asthma risk and significantly improves long-term rhinitis and asthma control-A RWE study.
    Jutel M; Klimek L; Richter H; Brüggenjürgen B; Vogelberg C
    Allergy; 2024 Apr; 79(4):1042-1051. PubMed ID: 38429981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Cost-Minimisation Analysis Comparing Sublingual Immunotherapy to Subcutaneous Immunotherapy for the Treatment of House Dust Mite Allergy in a Swedish Setting.
    Björstad Å; Cardell LO; Hahn-Pedersen J; Svärd M
    Clin Drug Investig; 2017 Jun; 37(6):541-549. PubMed ID: 28326466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. House dust mite subcutaneous immunotherapy has sustained long-term effectiveness on allergic rhinitis and asthma: A 10-year follow-up.
    Rodriguez-Plata E; Callero Viera A; Ruiz-Garcia M; Gomez-Cardenosa A; Nieto E; García-Robaina JC
    Immun Inflamm Dis; 2023 Oct; 11(10):e1004. PubMed ID: 37904678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.